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INTRODUCTION
Dapsone is a leprostatic agent commonly prescribed 
for the treatment of patients with leprosy, malaria, and 
a variety of blistering skin diseases, including derma-
titis herpetiformis. Methemoglobinemia, a potentially 
life-threatening condition in which the oxygen-carry-
ing capacity of blood in body tissues is reduced, is a 
known adverse effect of dapsone use. 
We report a case of dapsone-induced methemoglo-
binemia in a 64 year old woman whose condition was 
misdiagnosed by dermatologists as a flare of derma-
titis herpetiformis. This, in turn, caused them to pre-
scribe the wrong medication which led to acute dap-
sone-induced methemoglobinemia. This is a teaching 
case report as the doctor does not only need to make 
an initial diagnosis but also provide medical treatment 
appropriate to the histological anatomy diagnosis.
CASE REPORT
A 64-year old woman who was taking 100mg dap-
sone daily for dermatitis herpetiformis presented with 
a several-day history of weakness, and shortness of 
breath. 
She was noticeably cyanosed peripherally and 
centrally. Her vital signs included a blood pressure 
of 130/70 mm Hg; a body temperature of 36.7°C; a 
pulse of 90 beats per minute; a respiratory rate of 20 
breaths per minute; and an oxygen saturation of 89% 
with ambient air. The patient’s lungs were clear to 
auscultation. Skin examination revealed multiple ar-
eas of excoriation and swelling of the bilateral lower 
extremities. Central and peripheral cyanosis was not-
ed. Abdominal, cardiac, and neurologic examinations 
were unremarkable.
Initial investigations included a blood gas on ambi-
ent air: pH 7.36, PCO2 : 30,9, PO2: 96, HCO3: 17, met-
hemoglobin (metHb) level 14,7%. Complete blood 
count showed a hemoglobin level of 12.8g/dl, leuco-
cyte count of 5.8 with a normal differential count, and 
platelets of 185. Blood glucose, electrolytes, troponin, 
creatinine, alkaline phosphatase, transaminases, bili-
rubin, lipase, INR and PTT were normal. The patient 
was treated with discontinuation of dapsone, and use 
of diphenhydramine for the rash. During the 3 days af-
ter dapsone discontinuation the patient’s methemoglo-
bin level decreased to 1.8%, trending toward the nor-
mal range, and her oxygen saturation also improved. 
Direct immunofluorescence microscopy did not show 
granular IgA deposits which is often found continu-
ously along the dermal-epidermal junction rather than 
focally in the tips of the dermal papillae.
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DISCUSSION
Met-Hb1 is an oxidation product of Hb in which there 
is an oxidized ferric iron in the sixth co-ordination po-
sition instead of reduced ferrous iron in normal Hb. 
This oxidized ferric iron containing site is then bound 
to a water molecule or to a hydroxyl group. This com-
plex is dark brown and unable to transport oxygen 
with a leftward shift in oxygen dissociation curve, 
thus leading to a decreased tissue oxygenation with 
subsequent hypoxic features. 
There are two types of methemoglobinemia2,7 con-
genital and acquired:
Congenital methemoglobinemia is characterized 
by diminished enzymatic reduction of methemoglo-
bin back to functional hemoglobin. Affected patients 
appear cyanotic but are generally asymptomatic. 
Most cases of the less common hereditary methemo-
globinemias are due to homozygous or compound 
heterozygous deficiency (autosomal recessive) or in 
compound heterozygous cytochrome b5 reductase 
deficiency, which is primarily seen in sporadic cases. 
Another congenital cause of methemoglobinemia is 
hemoglobin M disease, which is due to mutations in a 
single globin gene ( autosomal dominant) of either the 
alpha, beta, or rarely gamma globin gene. Deficiency 
of cytochrome b5 is the rarest form of congenital met-
hemoglobinemia, and has been described in only one 
or two families.
Acquired methemoglobinemia typically results 
from ingestion of specific drugs or agents that cause 
an increase in the production of methemoglobin. It 
can be a fatal disease.
Dapsone3 (4,4’-diaminodiphenyl sulfone) is the 
parent compound of many sulfone medications, and 
has two primary toxicities: methemoglobinemia and 
hemolytic anemia.
It is absorbed from the gastrointestinal tract and 
undergoes enterohepatic circulation. Peak plasma 
concentrations are reached within 2 to 8 hours after 
ingestion. Mean half-life of plasma elimination var-
ies from 10 to up to 80 hours in overdose situations. 
Cyanosis is evident with only 1.5g/dL of metHb, in 
contrast to the 5g/dL of deoxygenated hemoglobin 
required to see hypoxia-related cyanosis6. Levels be-
tween 20-45% are associated with dyspnea, lethargy, 
dizziness, lightheadedness, weakness and headaches. 
MetHb levels above 45% are usually associated with 
impaired consciousness, and levels above 55% can 
cause seizures, coma and cardiac arrhythmias. The 
diagnosis of methemoglobinemia is based on clini-
cal symptoms and laboratory testing. Arterial blood 
gas analysis paired with oxygen saturation analysis 
by pulse oximetry are now considered the definitive 
measures for making a correct diagnosis of methe-
moglobinemia. Further evaluation of our patient’s 
medical history revealed that she had been medicating 
with dapsone in an effort to manage the rash on her 
lower extremities, which was believed to be derma-
titis herpetiformis. Dermatitis herpetiformis (DH) is 
a chronic pruritic cutaneous eruption associated with 
gluten-sensitive enteropathy (celiac disease [CD]) and 
immunoglobulin A (IgA) deposition in the skin. In our 
case direct immunofluorescence examinations, granu-
lar IgA deposition at the dermoepidermal junction 
with stippling in the dermal papillae, which is pathog-
nomonic of the condition, was negative.
Treatment4,5 consists of removing the inducing 
agent, administration of high-flow O2, observation, 
and evolutive co-oximetric assessment. After discon-
tinuation of the causative agent, fMetHb returns to 
baseline levels within 36 hours. The use of supple-
mentary O2 increases plasma levels of dissolved 
O2 and oxygen consumption during tissue hypoxia. 
Methylene blue is indicated as the first-line antidotal 
therapy for patients with severe methemoglobinemia. 
Although successful treatment with plasma exchange 
therapy, hyperbaric oxygen therapy and ascorbic acid 
has also been reported, these therapies should be con-
sidered as second-line treatments for patients unre-
sponsive to methylene blue.
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ΠΕΡΙΛΗΨΗ: Η Δαψόνη για πολλά χρόνια χρησιμοποιήθηκε ως θεραπεία εκλογής για την λέπρα αλλά και για πιο σπάνια 
δερματολογικά νοσήματα, ενώ σημαντικές παρενέργειες του φαρμάκου έχουν αναγνωριστεί. Η μεθαιμοσφαιριναιμία είναι 
μια σημαντική παρενέργεια της δαψόνης και περιγράφεται σε μια ασθενή που έλαβε το σκεύασμα αυτό.
Λέξεις Κλειδιά: Μεθαιμοσφαιριναιμία, Δαψόνη, Ερπητοειδής δερματίτις.
Μεθαιμοσφαιριναιμία από δαψόνη κατά την θεραπεία ερπητοειδούς δερματίτιδας.
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